Drug intelligence / Profile preview

Dimaval

Development stage: Phase 1
Lead developer: Heyl
Modality: Small Molecules
Administration: Oral, Intravenous, Intramuscular

Overview

Dimaval is a small molecule chelating agent developed by Heyl Chemisch-pharmazeutische Fabrik. Its active ingredient is sodium 2,3-dimercaptopropane-1-sulfonate (DMPS). The drug functions by utilizing two adjacent sulfhydryl (SH) groups to bind heavy metal ions, forming stable, water-soluble complexes that are primarily excreted through the kidneys. It is indicated for the treatment of acute and chronic poisoning from heavy metals, including mercury (organic and inorganic), lead, arsenic, bismuth, copper, and cobalt. Dimaval is available in oral capsule and injectable formulations and has been approved in Germany since 1997.

Brand names: Dimaval
Other names: DMPSsodium 2,3-dimercaptopropane-1-sulfonatedimercaptopropanesulfonic acidDimaval 100 mg HartkapselnDimaval100 mg HartkapselnDimaval-100 mg Hartkapseln

Beyond the preview

Go deeper on Dimaval.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dimaval.

Explore the full profile